Overactive Bladder
📧 Sign up to get email alerts when something new happens for Overactive Bladder.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2010-09-21Clinical Trial Update: Study of Urgent PC Versus Sham Effectiveness in Treatment of Overactive Bladder Symptoms [Phase 4]
A Phase 4 study evaluated the effectiveness of Urgent PC versus a sham procedure for treating overactive bladder symptoms, with results post…
-
FDA approval · 2010-09-20FDA Approved: OXYBUTYNIN CHLORIDE — Supplemental Application (Lannett Company, Inc.)
The FDA approved a supplemental application for oxybutynin chloride from Lannett Company, granting approval of a generic version of the drug…
-
CLINICAL_TRIALS trial_result · 2010-09-09Clinical Trial Update: Dose-Finding Study To Evaluate The Efficacy, Tolerability And Safety Of Fesoterodine In Comparison To Placebo For Overactive Bladder. [Phase 2]
Pfizer conducted a Phase 2 dose-finding trial comparing fesoterodine to placebo for efficacy, tolerability and safety in overactive bladder;…
-
CLINICAL_TRIALS trial_result · 2010-08-26Clinical Trial Update: Efficacy and Safety of Selective Serotonin Reuptake Inhibitor (SSRI) in Overactive Bladder Patients [Phase 4]
Phase 4 clinical trial update examining the efficacy and safety of a selective serotonin reuptake inhibitor in patients with overactive blad…
-
CLINICAL_TRIALS research · 2010-08-24Clinical Trial Update: Reproducibility Study of Overactive Bladder Symptom Score [OABSS]
The document reports the completion of a reproducibility study evaluating the Overactive Bladder Symptom Score (OABSS) for clinical trials.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2010-08-13FDA Approved: TROSPIUM CHLORIDE — Original Application (Glenmark Pharmaceuticals Inc., USA)
FDA approved Glenmark's original application for trospium chloride, enabling a generic version of the product.
-
CLINICAL_TRIALS trial_result · 2010-08-11Clinical Trial Update: Long Term Study To Evaluate the Safety, Tolerability and Efficacy of Fesoterodine for Overactive Bladder. [Phase 3]
Pfizer's long-term Phase 3 trial assessing the safety, tolerability, and efficacy of fesoterodine for overactive bladder has completed with …
-
CLINICAL_TRIALS trial_result · 2010-07-30Clinical Trial Update: Behavioral Modification and Vesicare Versus Vesicare Alone for Urge Incontinence in Patients With Overactive Bladder [Phase 3]
A Phase 3 trial comparing behavioral modification plus Vesicare (solifenacin) versus Vesicare alone for urge incontinence in adults with ove…
-
CLINICAL_TRIALS trial_result · 2010-07-27Clinical Trial Update: A Confirmatory Study of KUC-7483 in Patients With Overactive Bladder [Phase 3]
This update reports the completion of a Phase 3 confirmatory trial evaluating KUC-7483 for overactive bladder.
-
CLINICAL_TRIALS withdrawal · 2010-07-27Clinical Trial Update: Long-term Safety and Efficacy of KUC-7483 in Patients With Overactive Bladder [Phase 3]
Phase 3 trial evaluating KUC-7483 for overactive bladder has been withdrawn, ending the long-term safety and efficacy assessment.
-
CLINICAL_TRIALS trial_result · 2010-07-15Clinical Trial Update: Combined Anticholinergic Medication and Sacral Neuromodulation to Treat Refractory Overactive Bladder
A completed trial evaluating the combination of an anticholinergic medication with sacral neuromodulation for refractory overactive bladder.
-
FDA approval · 2010-07-12FDA Approved: VESICARE — Supplemental Application (Astellas Pharma US, Inc.)
The FDA approved a supplemental application for Vesicare (solifenacin succinate) from Astellas Pharma US, Inc., potentially updating the pro…
-
CLINICAL_TRIALS trial_result · 2010-06-24Clinical Trial Update: Intravesical Injection of Botox for Treating Therapy Refractory Overactive Bladder in Females
A completed clinical trial evaluated intravesical injections of Botox for therapy-refractory overactive bladder in women.
-
CLINICAL_TRIALS trial_result · 2010-05-26Clinical Trial Update: Screening Method in Sacral Neuromodulation
This trial update describes the screening method used in a sacral neuromodulation study for overactive bladder and urinary retention, with t…
-
CLINICAL_TRIALS trial_result · 2010-05-10Clinical Trial Update: A Comparison of a New Drug to Treat Overactive Bladder vs. Placebo [Phase 3]
Phase 3 trial results compare an investigational drug against placebo for overactive bladder; results have been posted from the completed st…
-
CLINICAL_TRIALS trial_result · 2010-04-30Clinical Trial Update: Post Marketing Surveillance Study on Emselex After Launch in Germany
A completed post-marketing surveillance study of Emselex (mirabegron) conducted in Germany to monitor safety after its launch for overactive…
-
CLINICAL_TRIALS trial_result · 2010-04-27Clinical Trial Update: Changes in Inflammatory and Contractile Protein Expression in Patients With Painful Bladder Syndrome/IC.
A completed clinical trial update reports changes in inflammatory and contractile protein expression in patients with Painful Bladder Syndro…
-
FDA approval · 2010-04-07FDA Approved: OXYBUTYNIN CHLORIDE — Supplemental Application (Chartwell RX, LLC)
FDA approved a supplemental application for oxybutynin chloride filed by Chartwell RX, LLC.
-
FDA approval · 2010-04-02FDA Approved: TOVIAZ — Supplemental Application (Pfizer Laboratories Div Pfizer Inc)
The FDA approved a supplemental application for Toviaz (fesoterodine fumarate) filed by Pfizer Laboratories Div Pfizer Inc, related to its l…
-
FDA approval · 2010-03-09FDA Approved: OXYBUTYNIN CHLORIDE — Supplemental Application (Teva Pharmaceuticals USA, Inc.)
FDA approved a supplemental application for oxybutynin chloride from Teva Pharmaceuticals USA, updating the product labeling.
-
FDA approval · 2010-03-09FDA Approved: OXYBUTYNIN CHLORIDE — Supplemental Application (Strides Pharma Science Limited)
FDA approved a supplemental application for oxybutynin chloride from Strides Pharma Science Limited.
-
FDA approval · 2010-03-03FDA Approved: OXYBUTYNIN CHLORIDE — Supplemental Application (Upsher-Smith Laboratories, LLC)
The FDA approved a supplemental application for oxybutynin chloride from Upsher-Smith Laboratories, LLC.
-
CLINICAL_TRIALS trial_result · 2010-02-11Clinical Trial Update: A Research Study for Patients With Overactive Bladder [Phase 2]
Phase 2 clinical trial sponsored by Allergan for overactive bladder and urinary incontinence has completed enrollment, with results posted o…
-
CLINICAL_TRIALS trial_result · 2010-01-11Clinical Trial Update: Study to Compare the Safety and Efficacy of Solifenacin With Oxybutynin for the Treatment of Overactive Bladder (VECTOR) [Phase 4]
Phase 4 clinical trial comparing solifenacin with oxybutynin for overactive bladder; the study is completed and results have been posted.
-
FDA approval · 2010-01-05FDA Approved: DETROL LA — Supplemental Application (Viatris Specialty LLC)
FDA approved a supplemental application for Detrol LA (tolterodine tartrate) filed by Viatris Specialty LLC.